Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

3 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.

Apalutamide offers similar HRQoL vs ADT alone in nonmetastatic castration-resistant prostate cancer

Christina Lau
12 Apr 2018

Men with nonmetastatic castration-resistant prostate cancer (CRPC) have similar health-related quality of life (HRQoL) with apalutamide given on top of androgen deprivation therapy (ADT) vs ADT alone, according to new data from the SPARTAN (Prostate Androgen Receptor Targeting with ARN-509) trial presented at the European Association of Urology (EAU) 2018 Congress.

In the phase III trial, 1,207 patients with nonmetastatic CRPC who had a prostate-specific antigen (PSA) doubling time of 10 months were randomized in a 2:1 ratio to receive oral apalutamide (240 mg daily) or placebo in addition to ADT (either with a gonadotropin-releasing hormone analogue or surgical castration). [N Engl J Med 2018;378:1408-1418]

After a median follow-up of 20.3 months, apalutamide was associated with a 72 percent reduction in the risk of metastasis and a 2-year extension in metastasis-free survival compared with placebo (median, 40.5 months vs 16.2 months; hazard ratio [HR], 0.28; p<0.0001). These results led to the US FDA’s approval of apalutamide in February 2018 as the first drug for nonmetastatic CRPC.

In the SPARTAN trial, patients’ HRQoL was assessed using self-reported questionnaires, including the Functional Assessment of Cancer Therapy-General (FACT-G), Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EuroQoL Group EQ-5D-3L questionnaires. These questionnaires were completed at baseline, on day 1 of cycles 2–7, cycle 9, cycle 11 and cycle 13, and subsequently every 4 months for the duration of treatment, as well as at 1 year after treatment discontinuation.

At baseline, the mean FACT-G score was 83/108 in the apalutamide arm and 84/108 in the placebo arm, which were comparable to the mean score of adult patients without prostate cancer (81/108).

Analysis showed that mean changes from baseline in FACT-P total score and all subscores were not significantly different between patients receiving apalutamide plus ADT and those receiving placebo plus ADT.

Furthermore, FACT-G scores and other patient-reported scores were maintained in the apalutamide arm.

“In fact, HRQoL was not only maintained in the apalutamide arm – it might be slightly better compared with patients in the placebo arm,” said co-investigator Professor Fred Saad of the University of Montreal in Quebec, Canada.

According to Saad, it was very important to evaluate the patients’ quality of life. “This is because patients with nonmetastatic CRPC are asymptomatic by definition, and treatment with an active agent could lead to a worsening in quality of life,” he explained.

“Our results also suggest that treatment with drugs such as apalutamide should not be delayed for patients with CRPC who are at high risk of metastasis,” Saad added. “Although patients in the placebo arm were treated with apalutamide upon the development of metastasis, the survival curves continued to separate between the two study arms. In other words, they did not do as well as patients who were started on apalutamide early.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

3 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.